Anzeige
❌
Mehr »
Mittwoch, 11.11.2026 - Börsentäglich über 12.000 News
Nach dem KI-Boom kommt Quantum: Warum Anleger jetzt auf Delta Gold schauen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
VI

WKN: A2PM7K | ISIN: US92858K2042 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVOS INC Chart 1 Jahr
5-Tage-Chart
VIVOS INC 5-Tage-Chart

Aktuelle News zur VIVOS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoVIVOS INC - 8-K, Current Report-
03.11.Vivos Inc. Announces Expansion of IsoPet Animal Cancer Division with Four New Veterinary Clinics Across the United States2
05.10.VIVOS INC - 8-K, Current Report1
18.08.Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center184Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, today announced...
► Artikel lesen
12.08.VIVOS INC - 10-Q, Quarterly Report1
VIVOS Aktie jetzt für 0€ handeln
27.07.Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update339Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy, is pleased to share this update on the meaningful advancements...
► Artikel lesen
06.07.Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel Precision Radionuclide Therapy521Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased...
► Artikel lesen
11.06.Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet Manufacturing292Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased...
► Artikel lesen
05.06.Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel Precision Radionuclide Therapy1
17.02.Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites443Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel Radionuclide Therapy (PRnT) is preparing to open two new production...
► Artikel lesen
10.02.Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel Precision Radionuclide Therapy387Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) with its innovative RadioGel technology, today...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1